A Transfer Factor felfedezése a legizgalmasabb dolog, ami az utóbbi évtizedekben az immunológiai kutatások területén történt.

A Transfer Factorok piciny, immunüzeneteket szállító molekulák, melyek magasabb rendű szervekben termelődnek. Szerepük az, hogy az immunrendszer sejtjei között immunológiai ismertetőjeleket közvetítsenek, és ezáltal segítsenek a még tanulatlan sejteknek ismereteket átadni a jelenlévő és a potenciális kórokozókról, veszélyekről.

Ezzel arra késztetik a szervezetet, hogy saját ölősejtjeinek mozgósításával hatékonyan védekezzen a kórokozók ellen. Például az anyatejben lévő Transfer Factorok segítségével tanul meg védekezni a csecsemők szervezete.

A Transfer Factorok szállítják, (transzferálják) a védekezéshez szükséges információt. A Transfer Factorok egész életünkben nagyon fontos szerepet játszanak szervezetünk védekezőképességében és ma már nagyon fontos szerepet játszanak a modern orvostudományban is.

A Transfer Factor felfedezése a legizgalmasabb dolog, ami az utóbbi évtizedekben az immunológiai kutatások területén történt.

A Transfer Factorok piciny, immunüzeneteket szállító molekulák, melyek magasabb rendű szervekben termelődnek. Szerepük az, hogy az immunrendszer sejtjei között immunológiai ismertetőjeleket közvetítsenek, és ezáltal segítsenek a még tanulatlan sejteknek ismereteket átadni a jelenlévő és a potenciális kórokozókról, veszélyekről.

Ezzel arra késztetik a szervezetet, hogy saját ölősejtjeinek mozgósításával hatékonyan védekezzen a kórokozók ellen. Például az anyatejben lévő Transfer Factorok segítségével tanul meg védekezni a csecsemők szervezete.

A Transfer Factorok szállítják, (transzferálják) a védekezéshez szükséges információt. A Transfer Factorok egész életünkben nagyon fontos szerepet játszanak szervezetünk védekezőképességében és ma már nagyon fontos szerepet játszanak a modern orvostudományban is.

A Transfer Factorokat sikeresen alkalmazták a következő betegségek terápiájában:

• vírusos fertőzések
• élősködők okozta megbetegedések
• autoimmun betegségek
• mycobaktérium-fertőzés
• gombás fertőzések
• rosszindulatú betegségek
• idegrendszeri problémák
• bakteriális eredetű fertőzések

A transfer factorok aktuális kutatási területei:

• Vírusos betegségek
• Herpesz
• Krónikus Fáradtság Szindróma
• Epstein-Barr vírus és Cytomegalovírus
• Hepatitis
• AIDS
• Más vírusok
• Gombás megbetegedések
• Mycobaktérium
• Bakteriális fertőzések
• Élősködők
• Rosszindulatú daganatok
• Autoimmun betegségek és idegrendszeri megbetegedés
• Fiatalkori reumás ízületi gyulladás
• Fiatalkori cukorbetegség
• Atópiás dermatits – Ekcéma
• Idiopátiás trombocitopéniás purpura
• Uveitis
• Lou Gehrig Szindróma (amitrófiás laterális szklerózis)
• Autizmus
• Alzheimer-kór
• Epilepszia
• Sclerosis Multiplex (SM).

Transfer factorokkal kapcsolatos néhány publikáció:

Personal communication with Richard Bennet, Ph.D. (11/17/97).
Immunology, Immunopathology and Immunity. Sell S. Appleton and Lange: Stamford CT 1996.
Allergenicity of orally administered immunoglobulin preparations in food-allergic children. Bernhisel-Broadbent J, Yolken RH, Sampson HA. Pediatrics 1991, 87(2), 208-14.
Transfer Factor in the Era of AIDS. Pizza G, Viza D. Biotherapy 1996, 9(1-3), ix-x.
Immunology in a Nutshell. Eberhand Wecker. Mannheim: BI. Wissenschaftverlag. 1992.
The cellular transfer of cutaneous hypersensitivity to tuberculin in man. Lawerence HS. Proc Soc Exp Biol Med 1949, 71, 516.
Activities and characteristics of Transfer Factors. Kirkpatrick CH. Biotherapy 1996, 9(1-3), 13-6.
Though scientifically easier to study, this isolation approach ignores the fact that multiple Transfer Factors are generated to a single infectious agent. Isolation of a single entity may even result in a significant loss in efficacy as has been observed in the attempted isolation of other biologically derived active materials.
Transfer Factor – current status and future prospects. Lawrence HS, Borowsky W. Biotherapy 1996, 9(1-3),1-5.
Personal communication from Drs. Greg Wilson and Gary Paddock.
Transfer Factor: Past, Present and Future. Fudenberg HH, Fudenberg HH. Ann Rev Pharm Tox 1989, 475-516
Murine Transfer Factors: dose-response relationships and routes of administration. Kirkpatrick C H, Hamad AR, Morton LC. Cell Immunol 1995, 164(2) 203-6.
In vitro studies during long-term oral administration of specific Transfer Factor. Pizza G, De Vinci C, Fornarola V, Palareti A, Baricordi O, Viza D. Biotherapy 1996, 9(1-3), 175-85.
Oral bovine Transfer Factor (OTF) use in the hyper-IgE syndrome. Jones JF, Schumacher MJ, Jeter WS & Hicks MJ. In: Immunobiology of Transfer Factor. Academic Press: New York. 1983, pp 261-70.
Observation of the effect of PSTF oral liquor on the positive tuberculin test reaction. Wu S, Zhong X. Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1992, 14(4), 314-6.
Modulation of concanavalin A-induced, antigen – non-specific regulatory cell activity by leuenkephalin and related peptides. Sizemore RC, Dienglewicz RL, Pecunia E, Gottlieb AA. Clin Imm Im 1991, 60(2), 310-18.
Use of In Vitro Assay Techniques to Measure Parameters Related to Clinical Applications of Transfer Factor Therapy. Wilson GB, Fudenberg HH. US Patent 4610878. Sept. 9, 1986.
Infectious Disease as an Evolutionary Paradigm. Lederberg J. The National Conference on Emerging Foodborne Pathogens: Implications and Control, March 24-26m 1997, Alexandria, Virginia, USA Emerging Infectious Diseases vol 3(4)
AIDS and Transfer Factor: myths, certainties and realities. Viza D, Biotherapy 1996, 9(1-3), 17-26.
A canine distemper virus epidemic in Serengeti lions (Panthera leo). Roelke-Parker ME, Munson L, Packer C, Kock R, Cleaveland S, Carpenter M, et al. Nature 1996, 379, 441-5.
Transfer Factor 1993: New frontiers. Fudenberg HH, Pizza G Progress in Drug Res. 1994 42, 309-400.
Transfer Factor in malignancy. Pizza G, De Vinci C, Fudenberg HH. Progress in Drug Research 1994, 42, 401-421.
Transfer Factor in the Era of AIDS. Proceedings of the Xth International Symposium on Transfer Factor. Bologna, Italy, 22-24 June 1995. Biotherapy 1996, 9(1-3), ix-x, 1-185.
Process for obtaining Transfer Factor from colostrum Transfer Factor so obtained and use thereof. Wilson GB, Paddock GV. Patent Number US4816563 Patent Date 1989-03-28.
Reasons for the emergence of antibiotic resistance. Tenover FC, McGowan JE Jr. Am J Med Sci 1996, 311(1), 9-16.
Antibiotic resistance: an ecological imbalance. Levy SB. Ciba Found Symp 1997, 207(1-9), 1-9; discussion 9-14.
Medline Search 1994-1997.
Antibiotic resistance in the staphylococci. Nobel WC. Sci Prog 1997, 80(1) 5-20.
Antibiotic resistance in pneumococci. Moreillon P, Wenger A. Schweiz Med Wochenschr 1996, 126(7), 25-63.
Antibiotic resistance pattern of Vibrio cholerae and Shigella causing diarrhea outbreaks in the eastern Africa region: 1994-1996. Materu SF, Lema OE, Mukunza HM, Adhiambo CG, Carter JY. East Afr Med J 1997,74(3), 193-7. Comment in: East Afr Med J 1997, 74(3) 121-3.
The effect of monitoring of antibiotic use on decreasing antibiotic resistance in the hospital. Giamarellou H, Antoniadou A. Ciba Found Symp 1997, 207, 76-86; 86-92.
Genetic basis of isonizazid resistance of Mycobacterium tuberculosis. Zhang Y. Res Microbiol 1993, 144(2), 143-149.
Strategies to minimize the development of antibiotic resistance. Baquero F, Negr. MC. J Chemother 1997, 9(3), 29-37.
Antibiotic resistance: epidemiology and strategies for prevention. Ansari M.Z.J Pak Med Assoc. 1995., 45(1), 18-23.
Personal communication with Dr. Greg Wilson (10/25/97)
Enterococci; increase in infection rate and antibiotic resistance. Thompson J. Ned Tijdschr Geneeskd 1996, 140(3), 130-3.
Antibiotic-resistance in Streptococcus pneumoniae. Krisher K. Adv Exp Med Biol 1995, 390, 123-40.
Antibiotic resistance in Streptococcus pneumoniae. Thomas A. Clin Infect Dis 24(1), S85-8.
Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL Pediatr Infect Dis J 1997, 16(4), 449-56.
Antibiotic resistance in group A streptococci. Gerber MA. Pediatr Clin North Am 1995, 42(3), 539-51.
Antibiotic resistance in Enterococcus species: an update. Eliopoulos GM. Curr Clin Top Infect Dis 1996, 16, 21-51.
Comparative assessment of Etest for testing susceptibilities of to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: Investigation using 510(k) review criteria, recommended by the Food and Drug Administration. Biedenbach DJ, Jones RN. J Clin Microbiol 1996, 34(12), 3214-3217.
Increasing antibiotic resistance of pneumococcus. Management of respiratory tract infections and meningitis. Kalin M, Eriksson M, Molstad S, Prellner K. Lakartidningen 1997, 94(12), 1061-4, 1067-8.
Antibiotic resistance in Neisseria Meningitidis. Oppenheim BA. Clin Infect Dis 1997, 24(Suppl 1), S98-101.
Antibiotic resistance mechanisms of mutant Escherichia coli. Kraal B, Zeef LA, MestersJR, Boon K, Vorstenbosch EL, Bosch L, Anborgh PH, Parmeggiani A, Hilgenfeld R. Biochem Cell Biol 1995, 73(11-12), 1167-77.
Antibiotic resistance. Bartlett JG, Frogatt JW, 3rd. Arch Otolaryngol Head Neck Surg 1995, 121(4), 392-6.
Mobile gene cassettes and intergrons: moving antibiotic resistance genes in gram-negative bacteria. Hall RM. Ciba Found Symp 1997, 207.ű, 192-202; discussion 202-5.
Antibiotic resistance: the current position and the molecular mechanisms involved. Hayward CM, Griffin GE. Br J Hosp Med 1994, 52(9), 473-8.
Antibiotic resistance: curent problems and prospects. Mazza P. Boll Chim Farm 1994 (133) 643-50.
Associated Press release, December 29, 1997.
Initial genetic characterization of the 1918 “Spanish” influenza virus. Taubenberger JK, Reid AH, Frafft AE, Bijwaard KE, Fanning TG. Science 1997, 275, 1793-6.
Gannett News Service October 8, 1997. Nature October 16, 1997.
The coming Holocaust: HIV expected to hit Asian economies hard. Friedland J. Far Eastern Economic Review 1994, 157(33), 15-16.
Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Ann.Inter.Med. 1991, 114(9), 798-802.
Political and economic roots of disease: malaria in Rajasthan. Mankodi K. Economic and Political Weekly 1996, 31(4), PE42-E48.
Basic helminthological issues in eastern Europe after the democratic changes. Kanev I, Petrov P, Komandarev S, Boeva KV, Kurdova R, Tanchev T, Filipov G, Dinev D,. Helminthologia 1995, 32(3), 117-120.
Rise in sexually transmitted diseases during democratization and economic crisis in Mongolia. Purevdawa E, Moon TD, Baigalmaa C, Davaajav K, Smith ML, Vermund Sh. Int J Std AIDS 1997, 8(6), 398-401.
NSTC-CISET Working Group on Emerginig and Reemerging Infectious Diseases. Infectious disease – a global health threat. Washington (CD): The Group; 1996
Emerging Foodborne Diseases: An Evolving Public Health Challenge. Tauxe RV. The National Conference on Emerging Foodborne Pathogens: Implications and Control, March24-26m 1997, Alexandria, Virginia, USA Emerging Infectious Diseases 1997, 3(4).
Epidemiology and Detection as Options for Control of Viral and Parasitic Foodborne Disease. Jaykus L-A. Emerging Infectious Diseases 1997, 3(4) [October-December Special Issue].
Waterborne Campylobacter in Sweden: the cost of an outbreak. Andersson Y, Jong B de, Studahl A. Water Science and Technology 1997, 35(11/12), 11-14.
Amending the Safe Drinking Water Act: View from Congress. Waxman H. EPA J 1994, 20(1-2), 32-33.
The Coming Plague. Laurie Garrett. Farrar Straus Press. 1994.
Health Aspects of Waste-Water Reuse for Irrigation of Crops. Reiff FM. In Non-Conventional Water Resources Use in Developing Countries. Proceedings of the Interregional Seminar, Willmstad, Curacao, Netherlands Antilles, April 22-28., 1985. p 245-259.
Biological Health Risks of Sludge Disposal. Block JC. In: Epidemiological Studies of Risks Associated with the Agricultural Use of Sewage Sludge: Knowledge and Needs. Elsevier Science Publishing Co., New York. 1986. p 123-134.
Recent UK Research on Incidence, Transmission and Control of Salmonella and Parasitic Ova in Sludge. Pike EB. In: Epidemiological Studies of Risks Associated with the Agricultural Use of Sewage Sludge: Knowledge and Needs. Elsevier Science Publishing Co., New York. 1986. p 50-59.
Wastewater Irrigation in Develpoing Countries: Health Effects and Technical Solutions. Shuval HI, Adin A, Fattal B, Rawitz E, Yekutiel R. World Bank Technical Paper No.51. The World Bank, Washington, DC. 1986. 324pp
Sewage Sludge as a Vector of Salmonellosis. Jones PW. In: Epidemiological Studies of Risks Associated with the Agricultural Use of Sewage Sludge: Knowledge and Needs. Elsevier Science Publishing Co., New York. 1986. p21-33.
Travel and the Emergence of Infectious Diseases. Wilson ME, M.D. Emerging Infectious Diseases 1995, 1(2)
Globalization, International Law, and Emerging Infectious Diseases. Fidler DP, J.D. Emerging Infectious Diseases 1996, 2(2)
The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the Americal Society for Microbiology Task Force on Antibiotic Resistance. Jones RN. Diagn Microbiol Infet Dis 1996,(25) 153-61.
Epidemiologic aspects on antibiotic resistance. Hoiby N. Microb Drug Resist 1995, 1(2), 137-42.
Child-care practices: effects of social change on the epidemiology of infectious diseases and antibiotic resistance. Holmes SJ, Morrow AL, Pickering LK. Epidemiol Rev 1996, 18(1), 10-28.
Streptococcus pneumoniae: impact of antibiotic resistance in pediatrics. Kaplan SL. Curr Probl Pediatr 1997, 27(5), 187-95.
Infections and antibiotic resistance in nursing homes. Nicolle LE, Strausbaugh LJ, Garibaldi RA. Clin Microbiol Rev 1996, 9(1), 1-17.
Respiratory tract infections: how frequent is antibiotic resistance? In vitro activity of older and recent antibiotics against the significant pathogens. Ruckdeschel G. Fortschr Med 1994, 112(33), 485-8.
Infentious agents and atherosclerotic vascular disease. Cook PJ, Lip GY. Q J Med 1996, 89(10), 727-35.
Infection and coronary heart disease. Ellis RW. J Med Microbiol 1997, 46(7), 535-9.
Virus infection and atherosclerosis. Wan L, Yang H, Yang Y. Shengli Kexue Jinzhan 1996, 27(3). CAS 126:129902
Incidence and pathophysiologic significance of infected carotid artery plaque. Paget CJ, Wolk SW, Whitehouse WM, Erlandson EE, Lampman RM, Schaldenbrand J, Fry WJ. Ann Vasc Surg 1997, 11(2), 129-32.
Can recombinant DNA technology provide useful vaccines against viruses which induce heart disease? Chapman NM, Tracy S. Eur Heart J 1995, 16(Suppl 0), 144-6.
Remedy containing antiviral agent for treatment of heart diseases associated with human hepatitis C. Patent # 9707820. CAS 126:220699
Cytomegalovirus and atherosclerosis. Chu A, Li J. Zhejiiang Yike Daxue Xuebao 1996, 25(4), 190-92. CAS 126:155721.
Role of cytomegalovirus and fibroblast growth factors in atherosclerosis. Dalvi SS. Diss. Abstr. Int., B 1996, 57(3), 1722. CAS 125:139522.
Significance of the adenine nucleotide translocator in the pathogenesis of viral heart disease. Mol. Cell. Biochem. 1996, 163/164, 319-327.
Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscles cells, and oxidiized low-density lipoprotein. Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Guetta E, Guetta V, Shibutani T, Epstein SE. Circ Res 1997, 81(1), 8-16.
Viral activationof coagulation: implications for thrombosis and atherosclerosis. Hajjar DP, Nicholson AC. Ann N Y Acad Sci 1997, 811, 155-65; discussion, 165-7.
Pain Free: the definitive guide to healing arthritis, low-back pain, and sports injuries through nutrition and supplements. Luke Bucci. The Summit Group: Fort Worth, TX. 1995.
Chronic Arthritis: Why the Joint? Proceedings of the Sixth Bertine Koperberg Conference 28-30 April 1994 in Nijegen, The Netherlands. Scandinavian Journal of Rheumatology 1995, Supplement 101.
Enterobacterial antigens with tropism for joint structures and HLA-B27 restricted cytotoxic T-cells in reactive arthirits. Hermann E. Scand J Rheum 1995, Suppl 101, 203-206.
Intestinal flora bacteria and arthritis: why the joint? Hazenberg MP Scand J Rheum 1995, Suppl 101, 207-212.
DLE in the therapy of juvenile chronic arthritis. Rovensky J, Rybar I, Orlovska M, Rauova L, Pekarek J. In: Recent Advances in Transfer Factor and Dialyzable Leucocytes Extracts. Fujisawa T, Sasakawa S, Iikura Y, Komatsu F, Yamaguchi Y (eds). Maruzen Co Ltd: Tokyo, Japan. 1992, pp 437-9.
Fat is an infectious issue, say researchers. Macready N. Lancet 1997, 349(9059), 1150.
A virally induced obesity syndrome in mice. Lyons MJ, Faust IJ, Hemmes RB, Buskirk DR Hirsch J, Zabriskie JB. Science 1982, 216 1(454) 182-5.
Virus-induced obesity in mice: association with a hypothalamic lesion. Nagashima K, Zabriskie JB, Lyons MJ. J Neuropathol Exp Neurol. 1992, 51(1), 101-9.
Evidence for an association of a virus with obesity in humans. Dhurandhar NV, Augusus A, Atkinson RL FASEB 1997, 11(3), 73-5.
Effect of anti-herpes specific Transfer Factor. Byston J, Cech K., Pekarek J, Jilkova J., Biotherapy 1996, 9 (1-3), 73-5.
Orally administered HSV-specific Transfer Factor prevents genital or labial herpes relapses. Pizza G, viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R. Biotherapy 1996, 9(1-3), 67-72.
Efficacy of Transfer Factor in treating patients with recurrent ocular herpes infections. Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G, Viza, D. Biotherapy 1996, 9(1-3), 61-6.
Clinical study of HSV-specific Transfer Factor on relapse HSVK. Anon. Xi’an Yike Daxue Yuebao 1996, 17(3), 322-324.
Transfer Factor prevents relapses in herpes keratitis patients: a pilot study. Pizza G, Meduri R, De Vinci C, Scorolli L, Viza D. Biotherapy 1994, 8(1), 63-8.
Personal experience with treatment of recurrent herpes infections using combined non-specific immunostimulation. Bystron J, Bohac S, Braunova J, Koukalova D. Cas Lek Cesk 1992, 131(5), 137-41.
The use of Transfer Factors in chronic fatigue syndrome: prospects and problems. Levin PH. Biotherapy 1996, 9(1-3), 87-90.
The use of Transfer Factors in chronic fatigue syndrome: prospects and problems. Levin PH. Biotherapy 1996, 9(1-3), 77-9.
Clinical, epidemiologic, and virologic studies in four cluster of the chronic fatigue syndrome, Levine PH, Jacobsen S, Pocinki AG, Cheney P, Peterson D, Connelly RR, Weil R, Ablashi DV, Salahuddin SZ, Pearson GR and Hoover, R. Arch Int Med 1992, 152: 1611-16.
Evaluation of the effects on acute hepatitis B treated with specific placenta Transfer Factor. Zhang GS, Hou XR, Zhao HC, Du QL, Wang GT Lin GX, In: Recent Advances in Transfer Factor an Dialyzable Leucocyte Extracts. Fujisawa T,Sasakawa S,Iikura Y,Komatsu F,Yamaguchi Y (eds), Maruzen Co, Ltd: Tokyo, Japan 1992,pp 217-21.
Compositions containing immunoribonucleic acids and immune Transfer Factors for controlling hepatitis A as well as hepatitis B. Jiang G, Yi B, Jiang G. Pat. Number 1098289 (1995-02-08) CAS 123:123162
Preparation of hepatitis B-specific immune Transfer Factor and immune RNA as vaccine for hepatitis B. Jiang G, Yi Y, Jiang G. Pat. Number 1098315 (1995-02-08) CAS 123:110148
Method for preparation of anti-b-hepatitis placental Transfer Factor. Zhang, Guangshu; Hou, Xianrong; Du, Qingling Pat. Number 1089843 (1994-07-27) CAS 122:170147
Preparation of highly specific Transfer Factor for treatment hepatitis B virus infection. Lin, Baoqiu; Dong, Qingjia. Pat Number 1084743 (1994-04-0) CAS 122:064292
The preparation and identification of specific Transfer Factor of hepatitis B virus. Li Q, Li D, Yuting Z, Wang L, Ren Z. Tianjin Yiyao 1994, 22(10), 586-8. CAS 122:185313.
Inhibition of in vitro HIV infection by dialyzable leukocyte extracts. Fernandez-Ortega C, Dubed M, Ruibal O, Vilarrubia OL, Menedez de San Pedro JC, Navea L, Ojeda M, Arana MJ. Biotherapy 1996, 9(1-3) 33-40.
Preliminary results in HIV-1 infected patients treated with Transfer Factor and zidovudine. Raise E, Guerra L, Viza D, Pizza G, De Vinci C, Schiattone ML, Rocaccio L, Cicognani M, Gritti F,. Biotherapy 1996., 9(1-3) 49-54.
Preliminary observations using HIV-specific Transfer Factor in AIDS. Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH, De Vinci C, Ciza D. Biotherapy 1996, 9(1-3) 41-7.
Dyalysable leucocyte extract (DLE) reduces lipopolysaccharide-induced tumour necrosis factor secreton in humar leucocytes. Ojeda Ojeda M,Fernandez Ortega CB, Arana Rosainz MJ. Biotherapy 1996, 9(1-3), 163-70.
T-cell proliferation in subinfectious SIV correlates with lack of infection after challenge of macaques. Clerici M, Clark E, Polacino P, Axberg I, Kuller L, Casey N, Morton W, Shearer G, and Benveniste R. AIDS 1994, 8, 1391-5.
Successful treatment of severe complicated measles with non-specific Transfer Factor. Ferrer-Argote VE, Romero-Cabello R, Hernandez-Mendza L, Arista-Viveros A, Rojo-Medina J, Balseca-Olivera F, Fierro M, Gonzalez-Constandse R. In Vivo 1994, 8(4), 555-7.
Study on the treatment of leprosy with Transfer Factor. Dang X, Jin Z. In: Research and Application of Transfer Factor and DLE. Bao-lai H, Ru-zhang W, Zhao-fen, Z (eds). Xueyuan Press: Bejing, China. 1989, pp 411-23.
Transfer Factor in chronic mucocutaneous candidiasis. Masi M, De Vinci C, Baricordi OR. Biotherapy 1996, 9(1-3), 97-103.
Treatment of chronic mucocutaneous candidias with Transfer Factor. Kirkpatrick CH, Greenberg LE. In: Immune Regulators in Transfer Factor. Khan A, Kirkpatrick CH, Hill NO (eds). Academic Press: New York. 1979.
Transfer Factor treatment of chronic mucocutaneous candidias: Requirement for donor reactivity to candida antigen. Littman BH, Rocklin RE, Parkman R. and David; Clin. Immuniol. Immunopathol, 1978, 9(97).
Immune abnormalities associated with chronic mucocutaneous candidiasis. H. Valdimarsson,.Higgs JM, Wells JM, Yamamara M, Hobbs JR, and Holt PJL. Cell. Immunol., 1973, 6 (348)
Use of Transfer Factor for the treatment of recurrent non-bacterial female cystitis (NBRC): a preliminary report. De Vinci C, Pizza G, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V, Viza D. Biotherapy 1996, 9(1-3), 133-8.
Stedman’s Medical Dictionary, 25th edition. William R. Hensyl (ed). Williams & Wilkins: Baltimore. 1989.
Immonotherapy of leprosy. Katoch K. Indian J Lepr 1996, 68(4), 349-61.
Preliminary results in the safety and efficacy of Transfer Factor in leprosy. Hastings RC, Morales Mj, Shannon EJ, Jacobson RR. In: Transfer Factor: Basic Properties and Clinical Applications. Asher MS, Gottlieb AA, Kirckpatrick CH (eds). Academic Press: New York. 1976, pp 465-76
The clinical use of specific Transfer Factors. Pekarek J, Cech K., Barnet K. In: Recent Advances in Transfer Factor and Dailyzable Leucocyte Extracts. Fujisawa T, Sasakawa S, Iikura Y, Konatsu F, Yamaguchi Y (eds). Maruzen Co, Ltd: Tokyo, Japan. 1992, pp 256-63
Treatment of Mycobacterium-fortuitum pulmonary infection with Transfer Factor (TF): New methodology for evaluating TF potency and predicting clinical response. Wilson GB, Metcalf JF Jr, Fudenburg HH. Clin Immunol Immunopathol, 1982, 23, 478
Mycobacterium fortuitum pulmonay infection associated with an antigen-selective defect in cellular immunity. Metcalf JF Jr, John JF Jr, Wilson GB, Fudenburg HH, Harley RA. Am J Med 1981, 71, 485
Cell-mediated immunity in chronic pyelonephritis. Zhang J.Chung Hsi I Chieh Ho Tsa Chih 1990, 10(7), 402-3, 388.
Dialyzable leukocyte extract used in the prevention of Salmonella infection in calves. Mikula I, Pistl J, Rosocha J. Vet Immunol Immunopathol 1992, 32(1-2), 113-24.
The use of mouse model for determination of protective activity in salmonella-specific leucocyte dialyzate. Mikula I, Pistl J. Acta Veterinaria Brno 1989, 58(2-3), 281-196
Immunostimulatory effects of certain substances in experimental ascaridiasis in pigs. Benkova M, Boroskova Z, Soltys J. Vet Med (Praha) 1992, 36(12), 717-24.
Preliminary results of Transfer Factor therapy of persistent cutaneous Leishmania infection. Sharma MK, Anaraki F, Ala F. Clin Immunol Immunopathol 1979, 12(183).
Shistosoma mansoni: reduction in clinical manifestations and in worm burdens conferred by serum and Transfer Factor from immune or normal rhesus monkeys. Maddison SE, Hicklin MD, Conway BP, Keegan IJ. Expl Parasit 1976, 39, (29-39)
A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. McMeeking A, Borkowski W, Klesius PH, Bonk S, Holzman RS, Lawrence HS.J Infect Dis 1990. 161, (108-12)
Treatment of Cryposporidiosis with oral bovine Transfer Factor. Louie E, Borkowsky WS, Klesius PH, Haynes TB, Gordon S. Clin Immunol Immunopathol 1987, 44(3), 329.
Personal communication from Dr. Nicholas Gonzales.
Radiprotective effects of DLE. Kofranek V, Barnet K, Pekarek J, Cech K. In: Research and Application of Transfer Factor and DLE. Huo B-L, Wang R-Z, Zou ZF (eds). Xueyuan Press. Bejing, China, 1989, pp 306-13.
The radioprotective effects of DLE-TF on BM mice. Kofranek V, Barnet K, Pekarek J, Cech K. In: Recent Advances in Transfer Factor and Dialyzable Leucocyte Extracts. Fujisawa T, Saskawa S, Iikkura Y, Komatsu F, Yamaguchi Y (eds). Maruzen Co Ltd: Tokyo, Japan. 1992, pp 306-13.
The adjuvant therapy of the nasopharyngeal tumor with Transfer Factor. Sibl O, Pekarek J, Cech K, Svejcar J. In: Research and Application of Transfer Factor. and DLE. Bao-lai H, Ruz-zhang W, Zhao-fen, Z (eds). Yueyuan Press: Bejing, China. 1989. pp 403-10.
DLE in immunosuppressed patients. Krystukova O, Cech K, Pekarek J, In: Recent advances in Transfer Factor and Dialyzable Leucocyte Extracts (eds) Fujisawa T, Saskawa S, Iikura Y, Komatsu F, Yamguchi Y. Maruzen Co Ltd: Tokyo, Japan. 1992, pp 315-22.
A preliminary report on the use of Transfer Factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Pizza G, De Vinci C, Cuzzocrea D, Memmiti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Plareti A, Zucchelli P, Fornarola V, Viza D. Biotherapy 1996, 9(1-3), 123-32.
Transfer Factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Pilotti V, Mastrorilli M, Pizza G, De Vinci, Busutti L, Palareti A, Gozzetti G, Cavallari A. Biotherapy 1996, 9(1-3), 117-21.
Adjuvant treatment using Transfer Factor for bronchogenic carcinoma: long-term follow-up. Whyte RI, Schork MA, Sloan H, Orringer MB, Kirsh MM. Ann Thorac Surg 1992, 53(3), 391-6.
Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Fujisawa T, Yamaguchi Y. Cancer 1996, 78(9), 1892-8.
Transfer Factor: clinical usage and experimental studies. A. Basten and S. Croft In: Immunological Engineering. Jirsch DW (ed). MTP Press Ltd, Falcon House: Lancaster, England. 1978, pp 83-120.
Immunological indicators in children with laryngeal papillomatosis and possible ways of immunocorrection. Garashchenko TI, Markova TP, Chuvirov DB. Vestn Otorinolaringol 1996(4), 15-8.
Infectious ‘self+X’ mosaics: an invitation to autoimmunity with potential for restoration by Transfer Factor. Lawrence HS. In: Infection and immunology in the rheumatic diseases. Dumonde DC (ed). Blackwell Scientific: Oxford. 1976, pp 563-77.
Influence of various forms of dialyzable leukocyte extracts on rat adjuvant arthritis. Stancikova M, Rovensky J, Pekarek J, Orvisky E, Blazickova S, Cech K. Archivum Immunologiae et Therapiae Experimentalis 1994, 42(4), 295-299.
Antipancreatic cellular hypersensitivity in diabetes mellitus. Nerups J, Andersen OO, Bendixen G. Diabetes 1971, 20 (424-7)
Islet cell surface antibodies in juvenile diabetes. Lernmark A, Freedman ZR, Hoffman C. N Engl J Med 1978, 299 (375-80)
Dialyzable lymphoid extract (DLE) from mice resistant to STZ-induced diabetogenesis can interrupt the progress of diabetes in STZ-treated CD-1 mice. Borkowsky W, Pilson R, Lawrence HS. Biotherapy 1996, 9(1-3), 149-57.
Transference factor in moderate and severe atopic dermatitis. Navarro CD, Serrano ME, Orea M, Estrada PS, Teran OL, Gomez VJ, Flores SG. Rev Alerg Mex 1996, 43(5), 116-23.
Leukocyte migration inhibition of buffy coats from patients with autimmune thrombocytopenic purpura when exposed to normal platelets: Modulation by Transfer Factor. Borkowsky, W.; Karpatkin, S., Blood 1984, 63(1), 83-87.
Cell Mediated Platelet Recognition by Leukocytes from Individuals with Auto Immune Thrombocytopenia and its Suppression by Human and Animal Transfer Factor. Borkowsky W, Karpatkin S. Pediatr Res 1984, 18(4 pt 2), 253a
Alternatives to steroid therapy in chronic uveitis. Klein S, Fricke HJ, Fricke B, Friedrich R, Illessy A, Schroder K D. Fortschr Ophthalmol 1990, 87(4), 355-8.
Low-molecular Transfer Factor and its use in the treatment of amyotrophic lateral sclerosis. Nevsimal O, Pekarek J, Koubek K, Cech K, Sonkova Z. Cesk Neurol Neurochir 1991, 54(4), 220-2.
Intrinsic and extrinsic determinants of neuronal development: relation to infantile autism. J Autism Dev Disord 1982, 12(2) 115-45.
Viral exposure and autism. Deykin EY, MacMahon B. Am J Epidemiol 1979, 109(6) 628-38.
Follow-up report on autism in congenital Rubella. Chess S. J Autism Child Schizophr 1977, 7(1) 69-81.
Behavioral consequences of congenital Rubella. Chess S, Fernandez P, Korn S. J Pediatr. 1978, 93(4) 699-703.
Depressed lymphocyte responsiveness in autistic children. Stubbs EG, Crawford ML. J Autism Child Schizophr 1977, 7(1), 49-55.
Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Fudenberg, HH. Biotherapy 1996, 9(1-3), 143-7.
Epileptic seizures and immune disorders. Mokran V, Simko M, Nyulassy S. Bratisl Lek Listy 1997, 98(4), 229-33.
Clinical observation on 37 cases of schizophrenia treated with Transfer Factor from bovine spleen. Xie D, Wang T, Huo B, Du X. In: Research and Application of Transfer Factor and DLE. Huo B, Wang R, Zou Z (eds). Xueyuan Press: Bejing, China. 1989, pp 354-6.
Serum antibodies to neurofilament antigens in patients with neurological and other diseases and in healthy controls. Bahmanyar S, Moreau-Dubois MC, Brown P, Cathala F, Gadjudsek DC. J Neuroimmunol 1983, 5(2), 191.
Immunopathology of hepatitis B antigen positive and negative active chronic hepatitis. Williams R. Dev Biol Stand 1975, 30, 341-9.
De novo initiation of specific cell-mediated immune responsiveness in chickens by Transfer Factor (specific immunity inducer) obtained from bovine colostrum and milk. Wilson GB, Poindexter C, Fort JD, Ludden KD. Acta Virol 1988, 32(1), 6-18.
Clinical applications of the continuous flow blood separator machine. Oon CJ, Hobbs JR. Clin Exp Immunol 1975, 20(1), 1-16.